CONSOLIDATED STATEMENTS OF CHANGES IN CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) - USD ($) $ in Thousands	Series A	Series B	Series C	Common Stock	Additional Paid-in Capital	Subscription Receivable.	Accumulated Deficit	Accumulated Other Comprehensive Loss	Total
Beginning balance at Dec. 31, 2020	$ 34,922	$ 144,839
Beginning balance (in shares) at Dec. 31, 2020	35,000,000	26,143,790
Increase (Decrease) in Temporary Equity [Roll Forward]
Issuance of Series C preferred stock, net			$ 159,628
Issuance of Series C preferred stock, net (in shares)			24,721,999
Ending balance at Mar. 31, 2021	$ 34,922	$ 144,839	$ 159,628
Ending balance (in shares) at Mar. 31, 2021	35,000,000	26,143,790	24,721,999
Beginning balance at Dec. 31, 2020				$ 1	$ 217,832	$ (31,900)	$ (292,342)	$ (3)	$ (106,412)
Beginning Balance (in shares) at Dec. 31, 2020				7,481,861
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Receipt of subscription receivable						31,900			31,900
Net assets contributed as result of merger					1,061				1,061
Issuance of common stock upon the exercise of stock options					47				47
Issuance of common stock upon the exercise of stock options (in shares)				40,790
Vesting of restricted stock (in shares)				150,799
Vesting of early exercise stock options					123				123
Vesting of early exercise stock options (in shares)				199,083
Unrealized gain (loss) on investments								(27)	(27)
Foreign currency translation								4	4
Stock based compensation					95				95
Net loss							(18,348)		(18,348)
Ending balance at Mar. 31, 2021				$ 1	219,158		(310,690)	(26)	(91,557)
Ending Balance (in shares) at Mar. 31, 2021				7,872,533
Beginning balance at Dec. 31, 2020	$ 34,922	$ 144,839
Beginning balance (in shares) at Dec. 31, 2020	35,000,000	26,143,790
Beginning balance at Dec. 31, 2020				$ 1	217,832	$ (31,900)	(292,342)	(3)	(106,412)
Beginning Balance (in shares) at Dec. 31, 2020				7,481,861
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Unrealized gain (loss) on investments									(28)
Foreign currency translation									(32)
Net loss									(67,630)
Ending balance at Sep. 30, 2021				$ 5	783,018		(359,972)	(63)	422,988
Ending Balance (in shares) at Sep. 30, 2021				54,641,380
Beginning balance at Mar. 31, 2021	$ 34,922	$ 144,839	$ 159,628
Beginning balance (in shares) at Mar. 31, 2021	35,000,000	26,143,790	24,721,999
Beginning balance at Mar. 31, 2021				$ 1	219,158		(310,690)	(26)	(91,557)
Beginning Balance (in shares) at Mar. 31, 2021				7,872,533
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock upon initial public offering, net of underwriting discounts and commissions and other issuance cost				$ 1	221,184				221,185
Issuance of common stock upon initial public offering, net of underwriting discounts and commissions and other issuance cost (in shares)				12,132,500
Conversion of convertible preferred stock upon initial public offering	$ (34,922)	$ (144,839)	$ (159,628)	$ 3	339,385				339,388
Conversion of convertible preferred stock upon initial public offering	(35,000,000)	(26,143,790)	(24,721,999)	34,126,528
Issuance of common stock upon the exercise of stock options					74				74
Issuance of common stock upon the exercise of stock options (in shares)				79,796
Vesting of restricted stock (in shares)				130,463
Vesting of early exercise stock options					46				46
Vesting of early exercise stock options (in shares)				62,271
Unrealized gain (loss) on investments								32	32
Foreign currency translation								(9)	(9)
Stock based compensation					1,711				1,711
Net loss							(23,273)		(23,273)
Ending balance at Jun. 30, 2021				$ 5	781,558		(333,963)	(3)	447,597
Ending Balance (in shares) at Jun. 30, 2021				54,404,091
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock upon initial public offering, net of underwriting discounts and commissions and other issuance cost					217				217
Issuance of common stock upon the exercise of stock options					9				9
Issuance of common stock upon the exercise of stock options (in shares)				6,799
Vesting of restricted stock (in shares)				148,347
Vesting of early exercise stock options					14				14
Vesting of early exercise stock options (in shares)				82,143
Unrealized gain (loss) on investments								(33)	(33)
Foreign currency translation								(27)	(27)
Stock based compensation					1,220				1,220
Net loss							(26,009)		(26,009)
Ending balance at Sep. 30, 2021				$ 5	783,018		(359,972)	(63)	422,988
Ending Balance (in shares) at Sep. 30, 2021				54,641,380
Beginning balance at Dec. 31, 2021				$ 5	785,049		(388,166)	(650)	396,238
Beginning Balance (in shares) at Dec. 31, 2021				55,005,523
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock upon initial public offering, net of underwriting discounts and commissions and other issuance cost				$ 1	26,812				26,813
Issuance of common stock upon initial public offering, net of underwriting discounts and commissions and other issuance cost (in shares)				2,160,760
Issuance of common stock upon the exercise of stock options					65				65
Issuance of common stock upon the exercise of stock options (in shares)				85,396
Vesting of restricted stock (in shares)				161,159
Vesting of early exercise stock options					673				673
Vesting of early exercise stock options (in shares)				173,192
Unrealized gain (loss) on investments								(1,986)	(1,986)
Foreign currency translation								(6)	(6)
Stock based compensation					2,380				2,380
Net loss							(37,512)		(37,512)
Ending balance at Mar. 31, 2022				$ 6	814,979		(425,679)	(2,642)	386,664
Ending Balance (in shares) at Mar. 31, 2022				57,586,030
Beginning balance at Dec. 31, 2021				$ 5	785,049		(388,166)	(650)	396,238
Beginning Balance (in shares) at Dec. 31, 2021				55,005,523
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Unrealized gain (loss) on investments									(2,931)
Foreign currency translation									(23)
Net loss									(99,250)
Ending balance at Sep. 30, 2022				$ 6	821,219		(487,416)	(3,604)	330,205
Ending Balance (in shares) at Sep. 30, 2022				58,184,655
Beginning balance at Mar. 31, 2022				$ 6	814,979		(425,679)	(2,642)	386,664
Beginning Balance (in shares) at Mar. 31, 2022				57,586,030
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock upon the exercise of stock options					47				47
Issuance of common stock upon the exercise of stock options (in shares)				31,381
Vesting of restricted stock (in shares)				136,425
Vesting of early exercise stock options					250				250
Vesting of early exercise stock options (in shares)				104,085
Unrealized gain (loss) on investments								(780)	(780)
Foreign currency translation								(12)	(12)
Stock based compensation					2,771				2,771
Net loss							(30,988)		(30,988)
Ending balance at Jun. 30, 2022				$ 6	818,047		(456,667)	(3,434)	357,952
Ending Balance (in shares) at Jun. 30, 2022				57,857,921
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock upon the exercise of stock options					138				138
Issuance of common stock upon the exercise of stock options (in shares)				86,224
Vesting of restricted stock (in shares)				136,425
Vesting of early exercise stock options					248				248
Vesting of early exercise stock options (in shares)				104,085
Unrealized gain (loss) on investments								(165)	(165)
Foreign currency translation								(5)	(5)
Stock based compensation					2,786				2,786
Net loss							(30,749)		(30,749)
Ending balance at Sep. 30, 2022				$ 6	$ 821,219		$ (487,416)	$ (3,604)	$ 330,205
Ending Balance (in shares) at Sep. 30, 2022				58,184,655